ClinicalTrials.Veeva

Menu

Gene Therapy Trial for the Treatment of X-linked Retinitis Pigmentosa Associated With Variants in the RPGR Gene

Janssen (J&J Innovative Medicine) logo

Janssen (J&J Innovative Medicine)

Status and phase

Completed
Phase 3

Conditions

X-Linked Retinitis Pigmentosa

Treatments

Biological: Genetic: AAV5-hRKp.RPGR

Study type

Interventional

Funder types

Industry

Identifiers

NCT04671433
2020-002873-88 (EudraCT Number)
MGT-RPGR-021
CR109258

Details and patient eligibility

About

A clinical trial of AAV5-RPGR vector for participants with X-linked retinitis pigmentosa (XLRP)

Enrollment

97 patients

Sex

All

Ages

3+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Male or female
  • 3 years of age or older
  • Has XLRP confirmed by a retinal specialist and has a predicted disease-causing sequence variant in RPGR confirmed by an accredited laboratory

Exclusion criteria

  • Has had ocular surgery within 3 months prior to screening or is anticipated to require ocular surgery within 6 months after the study intervention administration
  • Any investigational ocular treatment or any other ocular treatment that could confound the interpretation of the efficacy results or affect participant compliance with the visit schedule
  • Has undergone prior retinal surgery involving the macula, macular laser photocoagulation, external-beam radiation therapy, transpupillary thermotherapy, glaucoma filtration surgery or corneal surgery

Trial design

Primary purpose

Treatment

Allocation

Randomized

Interventional model

Parallel Assignment

Masking

Single Blind

97 participants in 3 patient groups

Experimental - Immediate Treatment
Experimental group
Description:
Intermediate dose.
Treatment:
Biological: Genetic: AAV5-hRKp.RPGR
Biological: Genetic: AAV5-hRKp.RPGR
Deferred Treatment
Other group
Description:
Deferred Treatment
Treatment:
Biological: Genetic: AAV5-hRKp.RPGR
Biological: Genetic: AAV5-hRKp.RPGR
Experimental Immediate Treatment
Experimental group
Description:
Low dose.
Treatment:
Biological: Genetic: AAV5-hRKp.RPGR
Biological: Genetic: AAV5-hRKp.RPGR

Trial contacts and locations

28

Loading...

Central trial contact

Study Contact

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems